RCUS Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -321.21% compared to Arcus Biosciences, Inc.'s net margin of 16.99%. Arcus Biosciences, Inc.'s return on equity of -67.06% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Arcus Biosciences, Inc. has a consensus price target of $34.20, signalling upside risk potential of 47.21%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that Arcus Biosciences, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Arcus Biosciences, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Arcus Biosciences, Inc. has a beta of 0.860, which suggesting that the stock is 13.987% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.

Arcus Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcus Biosciences, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Arcus Biosciences, Inc. quarterly revenues are $33M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Arcus Biosciences, Inc.'s net income of -$106M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Arcus Biosciences, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences, Inc. is 10.51x versus 11.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences, Inc. has a net margin of -321.21% compared to Arcus Biosciences, Inc.'s net margin of 27.44%. Arcus Biosciences, Inc.'s return on equity of -67.06% beat Gilead Sciences, Inc.'s return on equity of 41.72%.

Arcus Biosciences, Inc. has a consensus price target of $34.20, signalling upside risk potential of 47.21%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $157.43 which suggests that it could grow by 12.68%. Given that Arcus Biosciences, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Arcus Biosciences, Inc. is more attractive than Gilead Sciences, Inc..

Arcus Biosciences, Inc. has a beta of 0.860, which suggesting that the stock is 13.987% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.386, suggesting its less volatile than the S&P 500 by 61.417%.

Arcus Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.29% to investors and pays a quarterly dividend of $0.82 per share. Arcus Biosciences, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.6% of its earnings as a dividend. Gilead Sciences, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcus Biosciences, Inc. quarterly revenues are $33M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $8B. Arcus Biosciences, Inc.'s net income of -$106M is lower than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Arcus Biosciences, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 20.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences, Inc. is 10.51x versus 5.93x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -321.21% compared to Arcus Biosciences, Inc.'s net margin of 18.15%. Arcus Biosciences, Inc.'s return on equity of -67.06% beat Merck & Co., Inc.'s return on equity of 36.76%.

Arcus Biosciences, Inc. has a consensus price target of $34.20, signalling upside risk potential of 47.21%. On the other hand Merck & Co., Inc. has an analysts' consensus of $128.59 which suggests that it could grow by 6.11%. Given that Arcus Biosciences, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Arcus Biosciences, Inc. is more attractive than Merck & Co., Inc..

Arcus Biosciences, Inc. has a beta of 0.860, which suggesting that the stock is 13.987% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.446%.

Arcus Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.74% to investors and pays a quarterly dividend of $0.85 per share. Arcus Biosciences, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcus Biosciences, Inc. quarterly revenues are $33M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. Arcus Biosciences, Inc.'s net income of -$106M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Arcus Biosciences, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences, Inc. is 10.51x versus 4.67x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -321.21% compared to Arcus Biosciences, Inc.'s net margin of 21.74%. Arcus Biosciences, Inc.'s return on equity of -67.06% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Arcus Biosciences, Inc. has a consensus price target of $34.20, signalling upside risk potential of 47.21%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $872.70 which suggests that it could grow by 14.55%. Given that Arcus Biosciences, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Arcus Biosciences, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Arcus Biosciences, Inc. has a beta of 0.860, which suggesting that the stock is 13.987% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.238%.

Arcus Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.94 per share. Arcus Biosciences, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcus Biosciences, Inc. quarterly revenues are $33M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Arcus Biosciences, Inc.'s net income of -$106M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Arcus Biosciences, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences, Inc. is 10.51x versus 5.66x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.